Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Malignant Tumors × donafenib × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 18 Liver Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma 2 Recurrence 1 Pancreatic Neoplasms 1 Esophageal Neoplasms 1 Digestive System Neoplasms 1 Cirrhosis, Familial, with Pulmonary Hypertension 1 Biliary Tract Carcinoma 1 Biliary Tract Adenocarcinoma 1 Biliary Malignant Tumors 1

Interventions

donafenib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06685289 2025-01-28

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting

Gastrointestinal

Biliary Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡